SLC29A1 and leiomyosarcoma: Leiomyosarcoma patients treated with gemcitabine exhibited PFS of 6.8 months vs. 3.2 months, and OS of 14.9 months vs. 8.5 months in patients with high hENT1 and low hENT1 expression, respectively.